PT 141 – Product Information
PT-141 is a heavily modified synthetic derivative of an alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male/female hypoactive sexual desire disorder and acute hemorrhage. PT-141 is an agonist for the melanocortin-4 and melanocortin-1 receptors.
In the context of research, it is advisable to opt for bacteriostatic water when reconstituting substances rather than sterile water.
What is PT 141?
PT 141 is a synthetic peptide analog of alpha-MSH. Administration of PT-141 to normal men and patients with erectile dysfunction resulted in a dose-dependent increase in erectile activity. The results suggest that PT-141 holds promise as a potential new treatment for sexual dysfunction. [R]
Furthermore, the Food and Drug Administration (FDA) has already approved PT 141 to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in women. HSDD is characterized by low sexual desire. It is not due to a co-existing medical or psychiatric condition. [R]
Pure Rawz sells PT 141 for laboratory research use only.
How Does PT 141 Work?
PT 141 binds to specific melanocortin receptors (MCRs) in the brain. [R]
Melanocortin receptors are involved in a wide array of physiological functions. These receptors affect sexual function, pigmentation, energy homeostasis, and inflammation. Due to this, the MCR family has attracted considerable research activity. [R]
PT 141 activates MC1R, MC3R, and MC4R in the hypothalamus, affecting the area of the brain involved in sexual arousal. This phenomenon was observed following systemic administration of PT-141 to rats, which resulted in penile erections. [R]
PT 141 Vs. Melanotan-2
PT 141 and Melanotan-2 are synthetic analogs of alpha-MSH.
PT 141 is a synthetic derivative of Melanotan 2. In clinical trials, it has demonstrated its ability to increase sexual arousal in males and females. The FDA has approved PT 141 to treat sexual dysfunction in women with hypoactive sexual desire disorder (HSDD).
Melanotan II is similar to the natural MT-II hormone. It works by increasing the production of skin-darkening pigments in the body. MT-II may also promote sexual arousal. In two separate clinical trials, MT-II induced erections and tanning activity, respectively. [R] [R]
PT 141 Research
PT 141 was first mentioned in research literature in 2003. Since then, it has attracted many animal studies and clinical trials for its potential ability to treat sexual dysfunction in men and women. All these studies have shown that PT 141 holds immense potential.
PT 141 and Potential Sexual Desire in Female Subjects
A clinical trial was conducted to evaluate the effect of PT 141 on sexual arousal and desire in premenopausal female subjects with HSDD. Eighteen premenopausal subjects with a primary diagnosis of female sexual desire disorder were randomly assigned. [R]
Results showed that more subjects reported moderate or high sexual desire following PT 141 treatment vs. placebo. Among subjects who attempted sexual intercourse within 24 hours of treatment, significantly more were satisfied with their level of sexual arousal following PT 141 vs. placebo.
This preliminary evaluation suggests the potential for PT 141 to positively affect desire and arousal in subjects with female sexual desire disorder.
PT 141 and Potential Sexual Desire in Male Subjects
PT 141 was evaluated following intranasal administration in healthy male subjects and Viagra-response ED patients. In both studies, an erectile response induced by PT 141 administration was statistically significant, compared to placebo, at doses greater than 7mg. [R]
PT 141 was safely administered and well-tolerated in both studies, with flushing and nausea the most common adverse events reported. No clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed.
Based on its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED.
PT 141 and Erectile Dysfunction
Administration of PT-141 to patients with ED resulted in a dose-dependent increase in erectile activity. This drug resulted in erections occurring in 17 out of 20 men with ED. These results suggest that PT-141 holds promise as a new treatment for sexual dysfunction. [R] [R]
Another study was conducted to evaluate the effect of co-administration of PT-141 and sildenafil in patients with ED. The erectile response induced by co-administration of both drugs was significantly greater than the response elicited by the administration of sildenafil alone. [R]
Co-administration of PT-141 and sildenafil was safe and well-tolerated.
What are the side effects of PT 141?
According to the FDA, the most common side effects of PT 141 are nausea and vomiting, injection site reactions, flushing, and headache. About 40% of subjects in the clinical trials experienced nausea. [R]
What is the half-life of PT 141?
PT 141 is estimated to have a half-life of 1.9 to 2.7 hours.
What is the molecular formula of PT 141?
Is PT-141 Safe?
In studies involving healthy patients and subjects with ED, PT-141 was safely administered and well-tolerated. No clinically significant changes in vital signs, lab tests, ECGs, or physical exams were observed.
PureRawz sells PT 141 for research purposes and not for human consumption.
Where to Buy PT 141 Online
PureRawz is the best place to buy PT 141 for sale.
In order to be the best research chemicals supplier, we provide reference materials with every product we sell. Each of our products comes with an independent, third-party-issued Certificate of Analysis for identification, purity, and concentration.
We offer free international shipping on all orders above $100. You can pay for your purchase through various methods, including PayPal and Bitcoin. Click on the âReviewsâ tab to check out what existing customers say about our products and great customer service.
PT 141 appears to work by activating receptors in the central nervous system. It has shown immense potential as a potential treatment for ED in men. This drug has also helped treat female sexual dysfunction in women with HSDD clinical trials.